vaxigrip influenza vaccine 相關
廣告- www.creative-biolabs.com/Vaccine Design/Viral Vaccine
For Vaccines Research - Influenza Virus Vaccine
Provide global solution for worldwide customers in the field of viral vaccine development. Provides Vaccine CRO Services for Influenzavirus A/B/C/D, Isavirus, Thogotovirus.
搜尋結果
The 1957–1958 Asian flu pandemic was a global pandemic of influenza A virus subtype H2N2 that originated in Guizhou in Southern China.[3][4][1] The number of excess deaths caused by the pandemic is estimated to be 1–4 million around the world (1957–1958 and probably beyond), making it one of the deadliest pandemics in history.[1][2][5][6 ...
Vaccine storage relates to the proper vaccine storage and handling practices from their manufacture to the administration in people. [2] The general standard is the 2–8 °C cold chain for vaccine storage and transportation. This is used for all current US Food and Drug Administration (FDA)-licensed human vaccines and in low and middle-income ...
Pertussis vaccine is a vaccine that protects against whooping cough (pertussis). [1] [2] There are two main types: whole-cell vaccines and acellular vaccines. [1] [2] The whole-cell vaccine is about 78% effective while the acellular vaccine is 71–85% effective. [1] [3] The effectiveness of the vaccines appears to decrease by between 2 and 10% ...
Pandemrix is an influenza vaccine for influenza pandemics, such as the 2009 flu pandemic.The vaccine was developed by GlaxoSmithKline (GSK) and patented in September 2006. The vaccine was one of the H1N1 vaccines approved for use by the European Commission in September 2009, upon the recommendations of the European Medicines Agency (EMEA).
t. e. The 1918–1920 flu pandemic, also known as the Great Influenza epidemic or by the common misnomer Spanish flu, was an exceptionally deadly global influenza pandemic caused by the H1N1 influenza A virus. The earliest documented case was March 1918 in the state of Kansas in the United States, with further cases recorded in France, Germany ...
The COVID-19 vaccination program in Argentina is an ongoing effort of mass immunization. Vaccination against COVID-19 began in Argentina on 29 December 2020 aiming at health professionals. Argentina struck a deal with the United Kingdom in November 2020 for a British made vaccine produced by the pharmaceutical company AstraZeneca and the University of Oxford .
The most common and serious vaccine-preventable diseases tracked by the World Health Organization (WHO) are: diphtheria, Haemophilus influenzae serotype b infection, hepatitis B, measles, meningitis, mumps, pertussis, poliomyelitis, rubella, tetanus, tuberculosis, and yellow fever. [3] The WHO reports licensed vaccines being available to ...
